Expression And The Correlation Study Of Hepatoma-derived Growth Factor In Cholangiocarcinoma

Objective To detect the expression of HDGF ( hepatoma-derived growth factor ) in cholangiocarcinoma and analyze the relationship with clinicopathologic characteristic in cholangiocarcinoma.Methods HDGF expression in 30 patients withcholangiocarcinoma (18 males and 12 females) with ages ranging from 32 to 73 years (median, 51 years) was analyzed by immunohisto-chemistry. Samples with >90% of tumor cells to express positive immunoreactivity similar to or stronger than that in endothelial cells both for nucleus and cytoplasm were regarded as HDGF index level 2, and others as HDGF index level 1.Result (1)The positive rate of HDGF expression in cholangiocarcinoma was 86.7% for nucleus , 76.7% for cytoplasm, and that in peri-cancer tissue was 5.00% for nucleus, 45.0% for cytoplasm. There were statistical difference between them both for nucleus and cytoplasm(p<0.05 for both). (2) Twenty-one cases showed level 1 HDGF expression, whereas nine cases showed level 2 HDGF expression. Patients with level 2 expression showed higher rates of presence of lymph node metastasis(P < 0.05), poorer differentiated degree(P < 0.05), and poorer overall survival (P < 0.05) compared to those with level 1 expression. Multivariate analysis revealed HDGF expression level as an independent prognosticator for overall survival.Conclusion1.HDGF was highly expressed in cholangiocarcinoma and the expression of HDGF was associated with lymphatic metastasis and differentiated degree.2. HDGF expression level was shown to be a prognostic factor for cholangiocarcinoma.